gemcitabine has been researched along with Minimal Disease, Residual in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (5.88) | 29.6817 |
| 2010's | 14 (82.35) | 24.3611 |
| 2020's | 2 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Aron, M; Brummelhuis, ISG; Chau, A; Cutie, CJ; Daneshmand, S; Keegan, KA; Maffeo, JC; Pohar, KS; Raybold, B; Reynolds, DL; Steinberg, GD; Witjes, JA | 1 |
| Hussein, A; Razavi, M; Ren, G; Rezaee, M; Thakor, AS; Ullah, M; Wang, J; Zheng, F | 1 |
| Eurola, A; Haglund, C; Hagström, J; Mustonen, H; Nurmi, AM; Ristimäki, A; Seppänen, H | 1 |
| Bahary, N; Epelboym, I; Hamad, A; Hogg, ME; Lee, KK; Steve, J; Zeh, HJ; Zenati, MS; Zureikat, AH | 1 |
| Arena, J; Bergamin, S; Chua, TC; Clarke, S; Diakos, C; Gibbs, E; Gill, AJ; Hruby, G; Itchins, M; Kim, S; Kneebone, A; Maher, R; Mittal, A; Nahm, CB; Pavlakis, N; Rabindran, J; Samra, J; Wong, M | 1 |
| Bayerl, C; Breitenstein, S; Frei, L; Staerkle, RF; Stieger, R | 1 |
| Chabot, JA; Hecht, EM; Kluger, MD; Rashid, MF; Rosario, VL; Schrope, BA; Steinman, JA | 1 |
| Abdel-Wahab, M; Berriochoa, CA; Khorana, A; Kumar, AMS; Leyrer, CM; Matthew Walsh, R | 1 |
| Honda, G; Matsumoto, I; Motoi, F; Satoi, S; Shinchi, H; Sho, M; Tsuchida, A; Unno, M; Wada, K | 1 |
| Hashimoto, Y; Kondo, N; Murakami, Y; Muto, T; Nakagawa, N; Sasaki, H; Sudo, T; Sueda, T; Uemura, K; Urabe, K | 1 |
| Hanazaki, K; Iiyama, T; Iwata, J; Kobayashi, M; Kosaki, T; Kozuki, A; Morita, S; Okabayashi, T; Shima, Y; Sumiyoshi, T; Tokumaru, T | 1 |
| Bradley, WH; Eng, KH; Hanlon, BM; Szender, JB | 1 |
| du Bois, A; Grabowski, JP; Harter, P; Heitz, F; Heitz, J; Kristensen, G; Pfisterer, J; Pujade-Lauraine, E; Ray-Coquard, I; Reuss, A; Traut, A | 1 |
| Hashimoto, Y; Hatakeyama, S; Imai, A; Iwabuchi, I; Kawaguchi, T; Koie, T; Murasawa, H; Ogasawara, M; Ohyama, C; Yamamoto, H; Yoneyama, T | 1 |
| Inose, S; Karikomi, K; Kitamura, K; Koyama, M; Masamura, S; Matsumura, T; Nakamura, N; Okada, K; Suwa, T; Totsuka, E | 1 |
| Abou-Alfa, GK; Blumgart, LH; Capanu, M; D'Angelica, M; Dematteo, RP; Duffy, A; Fong, Y; Huitzil, D; Jarnagin, W; O'Reilly, EM | 1 |
| Brody, JR; Dasgupta, A; Kleer, CG; Potoczek, M; Toll, AD; Witkiewicz, AK; Yeo, CJ | 1 |
2 trial(s) available for gemcitabine and Minimal Disease, Residual
| Article | Year |
|---|---|
The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystectomy; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Muscles; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm, Residual; Urinary Bladder Neoplasms | 2022 |
A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Neutropenia; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prospective Studies; Survival Rate; Tegafur | 2019 |
15 other study(ies) available for gemcitabine and Minimal Disease, Residual
| Article | Year |
|---|---|
A Study Comparing the Effects of Targeted Intra-Arterial and Systemic Chemotherapy in an Orthotopic Mouse Model of Pancreatic Cancer.
Topics: Administration, Intravenous; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Mice; Mice, Nude; Neoplasm, Residual; Pancreatic Neoplasms; Transplantation, Heterologous | 2019 |
Impact of histological response after neoadjuvant therapy on podocalyxin as a prognostic marker in pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm, Residual; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Progression-Free Survival; Retrospective Studies; Risk Assessment; Sialoglycoproteins | 2021 |
Analysis of Perioperative Chemotherapy in Resected Pancreatic Cancer: Identifying the Number and Sequence of Chemotherapy Cycles Needed to Optimize Survival.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Lymph Node Excision; Male; Margins of Excision; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Neoplasm, Residual; Pancreatic Neoplasms; Perioperative Period; Proportional Hazards Models; Retrospective Studies; Survival Rate; Tumor Burden | 2017 |
Retrospective cohort analysis of neoadjuvant treatment and survival in resectable and borderline resectable pancreatic ductal adenocarcinoma in a high volume referral centre.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Hospitals, High-Volume; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Pancreatic Neoplasms; Positron-Emission Tomography; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Survival Rate | 2017 |
Resectable adenocarcinoma developing in the remnant pancreas 7 years after partial pancreatoduodenectomy for invasive ductal adenocarcinoma of the pancreas: a case report.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm, Residual; Neoplasms, Second Primary; Pancreatic Neoplasms; Pancreaticoduodenectomy; Positron Emission Tomography Computed Tomography; Time Factors | 2017 |
Resection of Locally Advanced Pancreatic Cancer without Regression of Arterial Encasement After Modern-Era Neoadjuvant Therapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Arteries; Celiac Artery; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease Progression; Drug Combinations; Female; Fluorouracil; Gemcitabine; Hepatic Artery; Humans; Irinotecan; Leucovorin; Male; Mesenteric Artery, Superior; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Neoplasms, Second Primary; Organometallic Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Progression-Free Survival; Radiosurgery; Radiotherapy, Intensity-Modulated; Survival Rate | 2018 |
Neoadjuvant chemoradiation for non-metastatic pancreatic cancer increases margin-negative and node-negative rates at resection.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation, Radiation; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Margins of Excision; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Organometallic Compounds; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy, Intensity-Modulated; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed; Tumor Burden | 2017 |
Perineural invasion in extrahepatic cholangiocarcinoma: prognostic impact and treatment strategies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Hepatectomy; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Neoplasm, Residual; Oxonic Acid; Peripheral Nerves; Proportional Hazards Models; Retrospective Studies; Survival Rate; Tegafur; Treatment Outcome | 2013 |
S-1 vs. gemcitabine as an adjuvant therapy after surgical resection for ductal adenocarcinoma of the pancreas.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm, Residual; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Tegafur | 2014 |
Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cytoreduction Surgical Procedures; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Taxoids; Time Factors; Topotecan | 2015 |
Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Case-Control Studies; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Cytoreduction Surgical Procedures; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Topotecan; Treatment Outcome; Young Adult | 2016 |
The utility of neoadjuvant gemcitabine plus carboplatin followed by immediate radical cystectomy in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Muscle, Smooth; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm, Residual; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms | 2017 |
[Regrowth of Isolated Local Residual Tumor Effectively Treated with Chemoradiotherapy More Than Five Years after a Resection for Pancreatic Cancer with an Involvement of the Portal Vein].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Neoplasm, Residual; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Portal Vein; Tegafur | 2016 |
Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Cholecystectomy; Cholecystectomy, Laparoscopic; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Hepatectomy; Humans; Incidental Findings; Male; Middle Aged; Neoplasm, Residual; Neuroendocrine Tumors; Radiotherapy, Adjuvant; Retrospective Studies; Sarcoma; Survival Analysis | 2008 |
Implications of enhancer of zeste homologue 2 expression in pancreatic ductal adenocarcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cadherins; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; DNA-Binding Proteins; Enhancer of Zeste Homolog 2 Protein; Female; Gemcitabine; Gene Silencing; Humans; Male; Middle Aged; Neoplasm, Residual; Pancreatectomy; Pancreatic Neoplasms; Pancreatitis, Chronic; Pennsylvania; Polycomb Repressive Complex 2; Survival Rate; Transcription Factors | 2010 |